<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89105">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987752</url>
  </required_header>
  <id_info>
    <org_study_id>190342-040</org_study_id>
    <nct_id>NCT01987752</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Combigan® Ophthalmic Solution in Korea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and
      efficacy of Combigan® (brimonidine tartrate/timolol maleate) Ophthalmic Solution in patients
      with Open Angle Glaucoma or Ocular hypertension with insufficient response to local beta
      blockers treated as per standard of care in clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Percentage of Participants Reporting Adverse Events</measure>
    <time_frame>Up to 2.6 Years</time_frame>
    <safety_issue>No</safety_issue>
    <description>An adverse event was any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>IOP is a measurement of the fluid pressure inside the eye. The study doctor classified the overall improvement of the IOP change from Baseline into 3 categories: Improvement (effective), No Change or Exacerbation (ineffective). The percentage of participants with Improvement is reported.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">732</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Combigan® Ophthalmic Solution</arm_group_label>
    <description>Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brimonidine tartrate/timolol maleate Ophthalmic Solution</intervention_name>
    <description>brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.</description>
    <arm_group_label>Combigan® Ophthalmic Solution</arm_group_label>
    <other_name>Combigan®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Open Angle Glaucoma or Ocular Hypertension treated with Combigan® Ophthalmic
        Solution in Clinical practice.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Open Angle Glaucoma or Ocular Hypertension treated with Combigan®
             Ophthalmic Solution as standard of care in clinical practice.

        Exclusion Criteria:

          -  None.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>November 13, 2013</firstreceived_date>
  <firstreceived_results_date>February 25, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combigan® Ophthalmic Solution</title>
          <description>Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="732"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="732"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combigan® Ophthalmic Solution</title>
          <description>Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="732"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt; 50 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="140"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>50 - 59 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="144"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>60 - 69 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="219"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>≥ 70 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="225"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Missing Data</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="347"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="384"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Missing Data</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Reporting Adverse Events</title>
        <description>An adverse event was any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.</description>
        <time_frame>Up to 2.6 Years</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety Population included all participants who received study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Combigan® Ophthalmic Solution</title>
            <description>Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="732"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Reporting Adverse Events</title>
            <description>An adverse event was any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)</title>
        <description>IOP is a measurement of the fluid pressure inside the eye. The study doctor classified the overall improvement of the IOP change from Baseline into 3 categories: Improvement (effective), No Change or Exacerbation (ineffective). The percentage of participants with Improvement is reported.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy Population included all participants who received study drug for &gt; 4 weeks and had overall assessment data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Combigan® Ophthalmic Solution</title>
            <description>Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="699"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)</title>
            <description>IOP is a measurement of the fluid pressure inside the eye. The study doctor classified the overall improvement of the IOP change from Baseline into 3 categories: Improvement (effective), No Change or Exacerbation (ineffective). The percentage of participants with Improvement is reported.</description>
            <units>Percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="85.69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President  GSE,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
